4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease

Lancet

Volumn 354, Issue 9178, 1999, Pages 556-560

  Hermans, Peter W M ^a   Hibberd, Martin L ^b   Booy, Robert ^c   Daramola, Olufunmilayo ^b   Hazelzet, Jan A ^a   De Groot, Ronald ^a   Levin, Michael ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ARTICLE; BLOOD CLOTTING DISORDER; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FIBRINOLYSIS; GENETIC PREDISPOSITION; GENOTYPE; HIGH RISK PATIENT; HUMAN; HYBRIDIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0033554250     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)02220-5     Document Type: Article

References (30)

1. Achtman M. Global epidemiology of meningococcal disease. Cartwright K. Meningococcal disease. 1995;159-177 John Wiley & Sons, Chichester.
2. Nadel S., Levin M., Habibi P. Treatment of meningococcal disease in childhood. Cartwright K. Meningococcal disease. 1995;207-243 John Wiley & Sons, Chichester.
3. Brandtzaeg P., Kierulf P., Gaustad P.et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis. 159:1989;195-204.
4. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock: association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 169:1989;333-338.
5. Speer C.P., Rethwilm M., Gahr M. Elastase-alpha 1-proteinase inhibitor: an early indicator of septicemia and bacterial meningitis in children. J Pediatr. 111:1987;667-671.
6. Osterud B., Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost. 49:1983;5-7.
7. Powars D.R., Rogers Z.R., Patch M.J., McGehee W.G., Francis R.B. Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S. N Engl J Med. 317:1987;571-572.
8. Brandtzaeg P., Mollnes T.E., Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis. 160:1989;58-65.
9. Hazelzet J.A., Risseeuw-Appel I.M., Kornelisse R.F.et al. Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost. 76:1996;932-938.
10. Brandtzaeg P., Sandset P.M., Joo G.B., Ovstebo R., Abildgaard U., Kierulf P. The quantitative association of plasma endotoxin, antithombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res. 55:1989;459-470.
11. Duncan A. New therapies for severe meningococcal disease but better outcomes? Lancet. 350:1997;1565-1566.
12. Kuppermann N., Inkelis S.H., Saladino R. The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans. Pediatr Infect Dis J. 13:1994;867-873.
13. Heyderman R.S., Klein N.J., Shennan G.I., Levin M. Deficiency of prostacyclin production in meningococcal shock. Arch Dis Child. 66:1991;1296-1299.
14. Smith O.P., White B., Vaughan D.et al. Use of protein-C concentrate, heparin, and haemofiltration in meningococcus-induced purpura fulminans. Lancet. 350:1997;1590-1593.
15. Fourrier F., Lestavel P., Chopin C.et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med. 16:1990;121-124.
16. Zenz W., Muntean W., Gallistl S., Zobel G., Grubbauer H.M. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics. 96:1995;144-148.
17. Drapkin M.S., Wisch J.S., Gelfand J.A., Cannon J.G., Dinarello C.A. Plasmapheresis for fulminant meningococcemia. Pediatr Infect Dis J. 9:1989;399-400.
18. Moore K.L., Andreoli S.P., Esmon N.L., Esmon C.T., Bang N.U. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 79:1987;124-130.
19. Engebretsen L.F., Kierulf O.P., Brandtzaeg P. Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Thromb Res. 42:1986;713-716.
20. Suffredini A.F., Harpel P.C., Parrillo J.E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 320:1989;1165-1172.
21. Pannekoek H., Veerman H., Lambers H.et al. Endothelial plasminogen activator inhibitor-1: a new member of the serpin gene family. EMBO J. 5:1986;2539-2544.
22. Gladson C.L., Schleef R.R., Binder B.R., Loskutoff D.J., Griffin J.H. A comparison between activated protein C and des-1-41-light chain-activated protein C in reactions with type 1 plasminogen activator inhibitor. Blood. 74:1989;173-181.
23. Ryan M.P., Kutz S.M., Higgins P.J. Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. Biochem J. 314:1996;1041-1046.
24. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 268:1993;10739-10745.
25. Kornelisse R.F., Hazelzet J.A., Savelkoul H.F.J.et al. The relationship between plasminogen activator inhibitor-1 and pro-inflammatory and counter-inflammatory mediators in children with meningococcal septic shock. J Infect Dis. 173:1996;1148-1156.
26. Derkx B., Wittes J., McCloskey R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin Infect Dis. 28:1999;770-777.
27. Esmon C.T., Taylor F.B., Snow R.T. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Throm Haemost. 66:1991;160-165.
28. Muta T., Iwanaga S. The role of hemolymph coagulation in innate immunity. Curr Opin Immunol. 8:1996;41-47.
29. Taylor F.B. Jr., Chang A., Esmon C.T., D'Angelo A., Vigano-D'Angelo S., Blick K.E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 79:1987;918-925.
30. Day K.C., Hoffman L.C., Palmier T.et al. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood. 76:1990;1538-1545.